Modality
Multispecific
MOA
PCSK9i
Target
CD3
Pathway
Apoptosis
FTDEoE
Development Pipeline
Preclinical
Nov 2025
→ Jan 2027
PreclinicalCurrent
NCT06287834
1,292 pts·EoE
2025-11→2027-01·Completed
1,292 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-01-2510mo awayInterim· EoE
Trial Timeline
2026Q2Q3Q42027
Preclinical
Complet…
Catalysts
Interim
2027-01-25 · 10mo away
EoE
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06287834 | Preclinical | EoE | Completed | 1292 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| INC-1261 | Incyte | Phase 1/2 | PRMT5 | |
| Mavutuximab | Hansoh Pharma | Phase 2/3 | PI3Kα |